Ranbaxy Laboratories Ltd (RANB.NS)

RANB.NS on National Stock Exchange of India

639.70INR
30 Sep 2014
Price Change (% chg)

Rs12.85 (+2.05%)
Prev Close
Rs626.85
Open
Rs631.00
Day's High
Rs642.65
Day's Low
Rs625.10
Volume
1,425,855
Avg. Vol
1,127,884
52-wk High
Rs667.60
52-wk Low
Rs305.20

RANB.NS

Chart for RANB.NS

About

Ranbaxy Laboratories Limited is an integrated international pharmaceuticals company. The Company is engaged in the marketing, production and distribution of pharmaceutical products. The Company’s business activity falls within a single primary business segment viz. Pharmaceutical. The Company has ground operations in over 40... (more)

Overall

Beta: 0.65
Market Cap (Mil.): Rs265,792.81
Shares Outstanding (Mil.): 424.01
Dividend: --
Yield (%): --

Financials

  RANB.NS Industry Sector
P/E (TTM): -- 33.26 33.98
EPS (TTM): -20.63 -- --
ROI: -- 18.14 17.39
ROE: -- 18.84 18.24
Search Stocks

CORRECTED-MARKET EYE-India's Sun Pharma head towards biggest daily gain in 5-1/2 months

(Changes 8th bullet point to say Ranbaxy is in the process of being acquired by Sun Pharma, and not yet a unit of Sun Pharma) * Sun Pharmaceutical Industries gains more than 6 pct. * Heads towards biggest single-day gain since April 9. * Credit Suisse says Sun has received a Form 483 from the U.S. FDA on a Gujarat facility. * FDA's Form 483 is a letter that notifies company of objectionable conditions * Traders say low chances of an import alert. * Credit Suisse notes the Form 483 given to S

26 Sep 2014

India caps prices of 36 more drugs to improve access: government official

NEW DELHI/MUMBAI - India has capped the prices of 36 drugs, including those used to treat infections and diabetes, in its latest move to make essential medicines more affordable, a senior official of the country's drug pricing authority told Reuters on Friday.

19 Sep 2014

UPDATE 2-India caps prices of 36 more drugs to improve access -govt official

* Local firms Cipla, Ranbaxy, Cadila among companies affected

19 Sep 2014

India's Ranbaxy says U.S. authorities seek information on pricing data

MUMBAI - Indian generic drugmaker Ranbaxy Laboratories Ltd said on Wednesday that federal authorities in the United States had sought details on how it reports pricing data for some products eligible for reimbursement under the Medicaid program.

17 Sep 2014

India's Ranbaxy says US authorities seek information on pricing data

MUMBAI, Sept 17 - Indian generic drugmaker Ranbaxy Laboratories Ltd said on Wednesday that federal authorities in the United States had sought details on how it reports pricing data for some products eligible for reimbursement under the Medicaid program.

17 Sep 2014

Epirus, Ranbaxy win India approval for arthritis drug copy

REUTERS - Epirus Biopharmaceuticals Inc said India's drug regulator has approved its copy of a top-selling arthritis treatment, paving the way for its launch in the country early next year.

16 Sep 2014

Epirus, Ranbaxy win India approval for arthritis drug copy

- Epirus Biopharmaceuticals Inc said India's drug regulator has approved its copy of a top-selling arthritis treatment, paving the way for its launch in the country early next year.

16 Sep 2014

Epirus, Ranbaxy win India approval for arthritis drug copy

Sept 15 - Epirus Biopharmaceuticals Inc said India's drug regulator has approved its copy of a top-selling arthritis treatment, paving the way for its launch in the country early next year.

16 Sep 2014

Gilead licenses hepatitis C drug to Cipla, Ranbaxy, five others

NEW DELHI/MUMBAI - U.S. drugmaker Gilead Sciences Inc has licensed its hepatitis C drug Sovaldi to seven India-based drugmakers that will sell far cheaper versions of the $1,000-a-pill medicine in 91 developing nations.

15 Sep 2014

Gilead licenses hepatitis C drug to Cipla, Ranbaxy, 5 others

NEW DELHI/MUMBAI, Sept 15 - U.S. drugmaker Gilead Sciences Inc said on Monday it has licensed its hepatitis C drug to seven companies including Cipla Ltd and Ranbaxy Laboratories Ltd to make it available in 91 developing countries including India.

15 Sep 2014

Earnings vs. Estimates

Search Stocks